We present a case report of a patient with metastatic non-small cell lung cancer (NSCLC) who had a series of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scans for assessment of response to treatment. A restaging 18F-FDG PET/CT scan after six cycles showed increased FDG activity in the bone lesions with reduced activity in the lung and liver lesions. The increased bone activity was considered to be due to flare phenomenon rather than metastasis. A short interval follow up scan after 1 month was advised to confirm this interpretation but this repeat scan showed disease relapse. Although the flare phenomenon does exist, caution should be exercised in attributing increased tracer uptake in the lesions in patients with adenocarcinoma of lung and especially those who have received erlotinib during the course of their treatment. Distinguishing the 'flare phenomenon' and 'disease progression' is at times difficult but is important since misdiagnosis may result in an unnecessary delay in patient management.
CASE REPORT
A 59-year-old male presented to his general practitioner with hoarseness of voice, reduced appetite and right hip and left shoulder pain. In addition, he complained of mild exertional dyspnoea but had no other significant chest symptoms. Chest radiography showed a mass in the upper lobe of the left lung and the baseline CT scan demonstrated a 3 cm spiculated mass and satellite nodules in the same lobe. Multiple metastatic lesions were found in the liver. In addition mediastinal and left hilar lymph node metastases were noted [Figures 1, 2] . Subsequent magnetic resonance imaging (MRI) of the spine confirmed bone metastases within the spine, sacrum and proximal femora [ Figure 3 ].
The baseline 18F-FDG PET/CT scan showed intense uptake in the 3 cm mass in the upper lobe of the left lung, mediastinal nodes, left hilar nodes and multiple liver and bone lesions [ Figure 4 ]. Chemotherapy (cisplatin and pemetrexed) and palliative radiotherapy were commenced after biopsy of the left scapular mass which showed an adenocarcinoma that demonstrated positive immuno-staining for CK7 (cytokeratin 7) and TTF1 (thyroid transcription factor-1) compatible with primary lung carcinoma [ Figure 5 ].
A follow-up 18F -FDG PET/CT scan after two cycles of chemotherapy showed a significant reduction in tracer avidity with mild uptake in the left upper lobe lung mass (maximum standardised uptake value (SUVmax) 3.2; previously 20.4) and multiple bone lesions (SUVmax 3.6; previously 8.4) . No uptake was seen in the mediastinal nodes, left hilar nodes or liver lesions.
After four cycles, 18F-FDG PET/CT scan demonstrated that uptake in the majority of the skeletal lesions and the chest lesions was unchanged, and the patient was therefore classified as having stable disease at this stage [ Figure 6a ]. Erlotinib [epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor] was added to the treatment regimen and a restaging 18F-FDG PET/CT was performed after six cycles of treatment which showed no significant tracer uptake in the lung nodules, mediastinal nodes or liver lesions. However, FDG uptake in the bone lesions showed a further increase in metabolic activity of about 51.5% (SUVmax 6.8 previously 3.5) [Figure 6 b] . Although the bone lesions now appeared sclerotic on CT, the pattern of FDG uptake was very unusual, with no uptake in the rest of the metastatic lesions. At this stage the bone lesion uptake was thought to represent a 'flare response phenomenon' rather than 'disease progression' [Figure 6 b] . A short-interval follow-up scan was advised, and repeat 18F-FDG PET/CT after a month showed evidence of disease relapse in the chest (mediastinal lymph nodes) and liver, with increased uptake in the bone lesions [ Figure 7 ]. This confirmed disease progression within the bone lesions rather than a 'flare response' as previously thought.
Lung cancer is the most common cancer in the world and accounts for 13% [1] of all new cases of cancer. NSCLC in turn accounts for 75-85% of all lung cancers (M:F ratio, 1.3:1). Tobacco smoking is one of the major risk factors for lung cancer and is considered the cause of death in as many as 90% of patients. The 5-year relative survival rate and the choice of treatment depend on the tumour stage at diagnosis [1, 2, 3] [ Table 1 ].
Various modalities are used to diagnose lung cancer and one should be aware of the differential diagnoses such as metastasis and benign lesions which may mimic the disease [ Table 2 ].
18F-FDG PET/CT has largely replaced technetium-99m methylene diphosphonate (99mTc-MDP) for the evaluation of suspected bone metastases. It is more sensitive and more specific than other currently available modalities for this purpose [4, 5, 6] . 18F-FDG PET/CT delineates the exact location of uptake in both osseous and non-osseous lesions, obviating the need for additional imaging. Patients with NSCLC have a 30%-40% likelihood of developing bone metastases [7] . The bony lesions in NSCLC are predominantly osteolytic but are occasionally osteoblastic (around 9%) [8] . In particular, it has been documented that adenocarcinoma of the lung may have osteoblastic bone deposits [8] . In addition, patients receiving erlotinib for NSCLC may develop osteoblastic bone lesions secondary to treatment response, and care should be exercised in recognising these features. As would be expected, response to treatment is reflected by a variable reduction in FDG uptake in almost all lesions. In some cases, however, there is increased uptake in bone lesions, seen both on 99mTc-MDP bone scan and on 18F-FDG PET/CT. This is attributed to the flare response phenomenon and is explained by increased osteoblastic activity at the site of metastatic bone lesions owing to the rapid repair; it accordingly represents response to treatment rather than disease progression. The flare response phenomenon has been described in the medical literature with regard to bone metastases secondary to breast and prostate cancer, as well as NSCLC [9-12].
18F-FDG PET/CT assesses the response to treatment by evaluating the reduction in metabolic activity in the primary tumour and metastases. In the reported case, there was a reduction in metabolic activity in the primary tumour and metastatic nodal and liver lesions during the course of the treatment, but increased metabolic activity in the bone lesions, i.e. FDG uptake in the bone metastases did not diminish, as would be expected. Technical errors were excluded to ensure that the increase in FDG activity was genuine, and the patient was erroneously considered to have the above-mentioned flare response following chemotherapy and radiotherapy. However, since no reliable markers can differentiate the flare phenomenon from disease progression, a short follow-up scan together with careful CT correlation should be performed in order to confirm or exclude disease relapse, and this approach was adopted in the reported case.
Awareness of this issue of disease progression versus flare phenomenon is especially important in patients with adenocarcinoma of lung and those who have received erlotinib during their course of treatment, such as our patient. This is because there is a tendency for NSCLC patients who have an EGFR gene mutation and are on erlotinib to show an osteoblastic flare response [2, 3] . Erlotinib acts by inhibiting EGFR and hence induces osteoblastic proliferation and prevents osteoclastic activation [2, 3] . This important potential pitfall needs to be borne in mind by clinicians when interpreting increased FDG uptake.
Awareness of the difficulty in distinguishing between the flare phenomenon and disease progression is important in enabling clinicians to avoid premature cessation of treatment or unnecessary changes in the treatment course, especially in patients with NSCLC (adenocarcinoma) who have been treated with erlotinib. Definitive diagnosis is possible only after shortinterval follow-up with 18F-FDG PET/CT. Follow-up 18F-FDG PET/CT scan after 1 month (CT/PET fused axial images, PET axial image). A 59 year old male with Non small cell lung cancer with metastasis. a) CT/PET fused axial images from whole-body 18F-FDG PET/CT scan obtained after 1 month of the scan labelling the patient with bone flare phenomenon. There is a 1 cm FDG avid hypodense liver lesion (thick arrow). b1, b2) CT/PET fused axial images and axial PET image from 18F-FDG PET/CT images obtained from the same scan show 18F-FDG avid soft tissue density in the AP window (thin arrow) which represents a metastatic lymph node. (Protocol: axial fused and axial PET images from 18F-FDG PET/CT scan, 120 kVp, 2.5 mm slice thickness, 422 MBq of 18F-FDG was injected and imaging was performed at 60 min).
Aetiology
Environmental and occupational factors and an individual's susceptibility to these agents are thought to contribute to risk of developing lung cancer.
Incidence
Lung cancer is the most common cancer in the world with 1.61 million new cases diagnosed every year. 13% of all new cases of cancer are lung cancers. NSCLC accounts for approximately 75-85% of all lung cancers.
Gender ratio
Male to female ratio is 1.3:1.
Age predilection
Most cases (87%) occur in people over the age of 60.
Risk factors
Smoking (78% in men, 90% in women), asbestos exposure, radon exposure, halogen ether exposure, chronic interstitial pneumonitis, inorganic arsenic exposure, radioisotope exposure, ionising radiation, atmospheric pollution, chromium exposure, nickel exposure, vinyl chloride.
Treatment
The treatment options depend on the stage of the cancer. For example, in patients with stage I or II NSCLC the treatment of choice is surgery. Radiation is often prescribed for patients with stage III disease or those with stage I or II disease in whom surgery is not performed. Chemotherapy provides only modest survival benefits (1-2 months) in disseminated NSCLC.
Prognosis
Stage I and II cancers have the highest survival and cure rates (5-year survival rate in stage I is 60-80%, and in stage II, 25-50%). Stage III tumours can be cured in some cases (5-year survival rate for stage IIIA is 10-40% and for stage IIIB, less than 5%). Patients with stage IV cancer that has returned are almost never cured (5-year survival rate is less than 5%); the goals of therapy are to extend and improve their quality of life.
Findings on imaging
Radiography CT MRI Nucl. Med.
Used for screening. Variable findings but the most common are: bronchial stenosis, regional hyperlucency, hilar mass, solitary pulmonary nodule and non-resolving pneumonia.
Used for evaluation of suspicious CXR findings and for staging of disease. Helps to differentiate between benign and malignant lesions based on lesion morphology.
Used for evaluation of local invasion and detection of hilar lymphadenopathy.
FDG PET scan has been used to differentiate benign from malignant pulmonary nodules, for staging of disease and for evaluation of response to treatment. 
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